The actual clinical relevance of this phenomenon was clearly outlined by Karapetis et al. [10], who assessed the impact of activating mutations in exon 2 of KRAS in cetuximab-treated patients with colorectal cancer. This evidence concerns the gene KRAS and colorectal cancer.